Breast Cancer

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.

Felipe Batalini, MD, details how targeting PIK3CA is evolving in breast cancer as new allosteric inhibitors have emerged and showed promising safety/efficacy.

Vered Stearns, MD, discusses the role of carboplatin in early-stage triple-negative breast cancer according to results from the phase 3 PEARLY trial.

Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.

Kevin Kalinsky, MD, MS, discusses outcomes of the phase 3 postMONARCH study in hormone receptor–positive, HER2-negative advanced breast cancer.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.

David Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.

Adjuvant ribociclib plus endocrine therapy was approved in Europe for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

China’s NMPA has approved sacituzumab tirumotecan for pretreated unresectable locally advanced or metastatic triple-negative breast cancer.

Vered Stearns, MD, discusses the efficacy of avelumab as adjuvant therapy in patients with early triple-negative breast cancer.

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

Jairam Krishnamurthy, MD, FACP, details what to take into consideration when implementing 2024 Breast Cancer NCCN guideline changes into everyday practice.

Ruth O'Regan, MD, discusses considerations for sequencing strategies in advanced hormone receptor–positive breast cancer.

Alberto Montero, MD, MBA, CPHQ, discusses the potential role for STX-478 in PIK3CA-mutant breast and gynecologic cancers.

Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.

Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer.

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Kari Wisinski, MD, highlights treatments for HER2– breast cancer, the role of chemotherapy in TNBC, and the benefits of T-DXd for brain metastases.

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.

Sheldon M. Feldman, MD, discusses the significance of the new classification of HER2-low breast cancer and how this affects HER2+ breast cancer treatment

Dana Zakalik, MD, discusses the critical role of genetic testing in managing breast cancer.

Alberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.

(Z)-endoxifen significantly reduced mammographic breast density and was generally well tolerated in premenopausal women screened for breast cancer.